Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity

Steatosis is a liver lesion reported with numerous pharmaceuticals. Prior studies showed that severe impairment of mitochondrial fatty acid oxidation (mtFAO) constantly leads to lipid accretion in liver. However, much less is known about the mechanism(s) of drug-induced steatosis in the absence of severe mitochondrial dysfunction, although previous studies suggested the involvement of mild-to-moderate inhibition of mtFAO, increased de novo lipogenesis (DNL), and impairment of very low-density lipoprotein (VLDL) secretion. The objective of our study, mainly carried out in human hepatoma HepaRG cells, was to investigate these 3 mechanisms with 12 drugs able to induce steatosis in human: amiodarone (AMIO, used as positive control), allopurinol (ALLO), d -penicillamine (DPEN), 5-fluorouracil (5FU), indinavir (INDI), indomethacin (INDO), methimazole (METHI), methotrexate (METHO), nifedipine (NIF), rifampicin (RIF), sulindac (SUL), and troglitazone (TRO). Hepatic cells were exposed to drugs for 4 days with concentrations decreasing ATP level by less than 30% as compared to control and not exceeding 100 ×  C max . Among the 12 drugs, AMIO, ALLO, 5FU, INDI, INDO, METHO, RIF, SUL, and TRO induced steatosis in HepaRG cells. AMIO, INDO, and RIF decreased mtFAO. AMIO, INDO, and SUL enhanced DNL. ALLO, 5FU, INDI, INDO, SUL, RIF, and TRO impaired VLDL secretion. These seven drugs reduced the mRNA level of genes playing a major role in VLDL assembly and also induced endoplasmic reticulum (ER) stress. Thus, in the absence of severe mitochondrial dysfunction, drug-induced steatosis can be triggered by different mechanisms, although impairment of VLDL secretion seems more frequently involved, possibly as a consequence of ER stress.

• Publication year

  2020

• Venue

  Cell Biology and Toxicology

• Publication date

  2020-06-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10565-020-09537-1PMID 32535746PMCID 8012331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug-induced liver injury in obesity and nonalcoholic fatty liver disease.

  2019influential reference
• Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis

  2019influential reference
• Allopurinol Prevents the Lipogenic Response Induced by an Acute Oral Fructose Challenge in Short-Term Fructose Fed Rats

  2019cited by this paper
• Frequent Modulation of the Sterol Regulatory Element Binding Protein (SREBP) by Chemical Exposure in the Livers of Rats.

  2019cited by this paper
• A gene expression biomarker identifies factors that modulate sterol regulatory element binding protein

  2019influential reference
• Metabolomics profiling of steatosis progression in HepaRG® cells using sodium valproate.

  2018cited by this paper
• Alcoholic liver disease

  2018cited by this paper
• Alcoholic liver disease

  2018cited by this paper
• Prolactin improves hepatic steatosis via CD36 pathway.

  2018cited by this paper
• Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides

  2018cited by this paper
• Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells

  2018cited by this paper
• Possible Involvement of Mitochondrial Dysfunction and Oxidative Stress in a Cellular Model of NAFLD Progression Induced by Benzo[a]pyrene/Ethanol CoExposure

  2018cited by this paper
• Mechanisms of Tauroursodeoxycholate-Mediated Hepatoprotection

  2017cited by this paper
• Chronic and low exposure to a pharmaceutical cocktail induces mitochondrial dysfunction in liver and hyperglycemia: Differential responses between lean and obese mice

  2017influential reference
• Endoplasmic Reticulum Stress Inducer Tunicamycin Alters Hepatic Energy Homeostasis in Mice

  2017influential reference
• Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor γ in Mouse Liver

  2016influential reference
• Endoplasmic reticulum proteostasis in hepatic steatosis

  2016cited by this paper
• Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis.

  2016influential reference
• Role of endoplasmic reticulum stress in drug‐induced toxicity

  2016influential reference
• Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice

  2016cited by this paper
• Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice.

  2015cited by this paper
• Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.

  2015cited by this paper
• Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein

  2015cited by this paper
• Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs

  2015influential reference
• In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments.

  2015cited by this paper
• Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S]

  2015influential reference
• Drug-induced fatty liver disease: An overview of pathogenesis and management.

  2015cited by this paper
• Metabolic vulnerabilities in endometrial cancer.

  2014cited by this paper
• Getting RIDD of RNA: IRE1 in cell fate regulation.

  2014influential reference
• Comparative Analysis of the Cytotoxic Effects of Okadaic Acid-Group Toxins on Human Intestinal Cell Lines

  2014cited by this paper
• How does protein misfolding in the endoplasmic reticulum affect lipid metabolism in the liver?

  2014influential reference
• Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion

  2014influential reference
• A simple transcriptomic signature able to predict drug-induced hepatic steatosis

  2014cited by this paper
• Model Steatogenic Compounds (Amiodarone, Valproic Acid, and Tetracycline) Alter Lipid Metabolism by Different Mechanisms in Mouse Liver Slices

  2014cited by this paper
• Whole Genome Transcript Profiling of Drug Induced Steatosis in Rats Reveals a Gene Signature Predictive of Outcome

  2014cited by this paper
• Endoplasmic Reticulum Stress in Drug- and Environmental Toxicant-Induced Liver Toxicity

  2014influential reference
• Drug-Induced Hepatic Steatosis

  2014influential reference
• A unifying ontology to integrate histological and clinical observations for drug-induced liver injury.

  2013cited by this paper
• Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis

  2013influential reference
• Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease

  2013cited by this paper
• Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes.

  2013cited by this paper
• Drug-induced steatohepatitis.

  2013cited by this paper
• Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria

  2012cited by this paper
• Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

  2012cited by this paper
• Differing Endoplasmic Reticulum Stress Response to Excess Lipogenesis versus Lipid Oversupply in Relation to Hepatic Steatosis and Insulin Resistance

  2012cited by this paper
• Alcoholic liver disease.

  2012influential reference
• The contribution of endoplasmic reticulum stress to liver diseases

  2011cited by this paper
• Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration.

  2011influential reference
• Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells

  2011influential reference
• Hepatic autophagy mediates endoplasmic reticulum stress–induced degradation of misfolded apolipoprotein B

  2011cited by this paper
• Endoplasmic Reticulum Stress and Lipid Metabolism: Mechanisms and Therapeutic Potential

  2011cited by this paper
• The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease

  2011cited by this paper
• Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.

  2011influential reference
• Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.

  2010cited by this paper
• Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome

  2010influential reference
• Induction of Liver Steatosis and Lipid Droplet Formation in ATF6α-Knockout Mice Burdened with Pharmacological Endoplasmic Reticulum Stress

  2010influential reference
• Identification of a consensus element recognized and cleaved by IRE1α

  2010cited by this paper
• N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes.

  2009cited by this paper
• Glucosamine-induced endoplasmic reticulum stress attenuates apolipoprotein B100 synthesis via PERK signaling

  2009influential reference
• UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators.

  2008influential reference
• Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents.

  2008cited by this paper
• Cellular imaging predictions of clinical drug-induced liver injury.

  2008influential reference
• PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

  2005cited by this paper
• PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes

  2005cited by this paper
• Real-time flow cytometry analysis of permeability transition in isolated mitochondria.

  2004cited by this paper
• Drug-induced liver injury.

  2004cited by this paper
• Disruption of Hepatic Lipid Homeostasis in Mice after Amiodarone Treatment Is Associated with Peroxisome Proliferator-Activated Receptor-αTarget Gene Activation

  2004cited by this paper
• Drug-induced steatohepatitis.

  2003cited by this paper
• Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug‐induced steatosis in mice

  2003cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Acetaminophen-induced inhibition of Fas receptor-mediated liver cell apoptosis: mitochondrial dysfunction versus glutathione depletion.

  2002cited by this paper
• Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria.

  2001influential reference
• Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176.

  2001cited by this paper
• HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis

  2000cited by this paper
• [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].

  1999influential reference
• Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

  1996cited by this paper
• Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables

  1995cited by this paper
• Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.

  1995influential reference
• Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice.

  1990cited by this paper
• Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II.

  1990influential reference
• Potency of polyunsaturated and saturated fats as short-term inhibitors of hepatic lipogenesis in rats.

  1990cited by this paper
• Nile red: a selective fluorescent stain for intracellular lipid droplets

  1985cited by this paper
• Alcoholic liver disease.

  1977cited by this paper

• Mitochondrial dysfunction in drug-induced hepatic steatosis: recent findings and current concept.

  2025cites this paper
• Mechanism-based new approach methodologies for in vitro detection of chemical-induced liver steatosis.

  2025cites this paper
• A large-scale human toxicogenomics resource for drug-induced liver injury prediction

  2025cites this paper
• A mechanistically-anchored and human stem cell-based in vitro test battery for assessing liver steatogenic potential of chemicals.

  2025cites this paper
• The Lipidome Landscape of Amiodarone Toxicity: An in vivo Lipid-centric Multi-Omics Study

  2025cites this paper
• A strategy to detect metabolic changes induced by exposure to chemicals from large sets of condition-specific metabolic models computed with enumeration techniques

  2024cites this paper
• Mechanisms of hepatocellular toxicity associated with the components of St. John's Wort extract hypericin and hyperforin in HepG2 and HepaRG cells.

  2024cites this paper
• Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals.

  2024cites this paper
• Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways

  2024cites this paper
• A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction.

  2024cites this paper
• The dithiocarbamate pesticides maneb and mancozeb disturb the metabolism of lipids and xenobiotics in an in vitro model of metabolic dysfunction-associated steatotic liver disease

  2024influential citation
• Comparison of in vitro models for drug-induced liver injury assessment

  2024cites this paper
• PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

  2024cites this paper
• Rifampicin-induced ER stress and excessive cytoplasmic vacuolization instigate hepatotoxicity via alternate programmed cell death paraptosis in vitro and in vivo.

  2023cites this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cites this paper
• In vitro to in vivo extrapolation and high-content imaging for simultaneous characterization of chemically induced liver steatosis and markers of hepatotoxicity

  2023cites this paper
• Development of a reference and proficiency chemical list for human steatosis endpoints in vitro

  2023cites this paper
• 3D multi-cell-type liver organoids: A new model of non-alcoholic fatty liver disease for drug safety assessments.

  2023cites this paper
• Busulfan induces steatosis in HepaRG cells but not in primary human hepatocytes: Possible explanations and implication for the prediction of drug‐induced liver injury

  2023influential citation
• S07-03 Mitochondrial toxicity as a mechanism of xenobiotic-induced steatosis and steatohepatitis

  2023cites this paper
• Drug induced liver injury – a 2023 update

  2023cites this paper
• Methotrexate-Induced Liver Injury Is Associated with Oxidative Stress, Impaired Mitochondrial Respiration, and Endoplasmic Reticulum Stress In Vitro

  2022cites this paper
• Transcriptional and Epigenetic Consequences of DMSO Treatment on HepaRG Cells

  2022cites this paper
• Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis

  2022cites this paper
• Dietary zero-dimensional fullerene supplementation improves the meat quality, lipid metabolism, muscle fiber characteristics, and antioxidative status in finishing pigs

  2022influential citation
• Mitochondrial alterations in fatty liver diseases.

  2022cites this paper
• Liposome-Mediated Gene Transfer in Differentiated HepaRG™ Cells: Expression of Liver Specific Functions and Application to the Cytochrome P450 2D6 Expression

  2022cites this paper
• Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update

  2022cites this paper
• Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease

  2022cites this paper
• Chemical screening of food-related chemicals for human fatty liver risk: Combining high content imaging of cellular responses with in vitro to in vivo extrapolation

  2022cites this paper
• Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta‐analysis

  2021cites this paper
• An eight-compound mixture but not corresponding concentrations of individual chemicals induces triglyceride accumulation in human liver cells.

  2021cites this paper
• Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models

  2021influential citation
• Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients

  2021cites this paper
• Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

  2020influential citation